Andere talen HLS Therapeutics Inc.

Aandelen

HLS

CA40390B1094

Vertraagde tijd Toronto S.E. Andere beurzen 16:37:59 08-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
4,78 ^CAD	+1,06%		+2,80%	+21,01%

08/04	HLS Therapeutics Inc. kondigt de resultaten aan van de Reduce-IT analyse met betrekking tot de effecten van VASCEPA	CI
14/03	Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call	25/04
HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	09/04
HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA	08/04
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups	08/04
HLS Therapeutics Reports Q4 2023 Net Loss of US$5.4 Million; Provides 2024 Outlook, Credit Agreement Update	14/03
HLS Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
HLS Therapeutics Brief: Q4 2023 and fiscal 2023 product sales in Canada increased 11% and 10%, respectively, in CAD, compared to same periods in 2022	14/03
HLS Therapeutics Brief: Q4 2023 revenue was US$15.9 million, Adjusted EBITDA was $5.3 million and cash from operations was $3.7 million	14/03
HLS Therapeutics Announces Fiscal 2023 Financial Results	14/03
HLS Therapeutics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2024	14/03
HLS Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/03
HLS Therapeutics to Host Q4 and Fiscal 2023 Financial Results Conference Call	29/02
HLS Announces that Vascepa is now reimbursed by British Columbia's Provincial Drug Plan	07/02
HLS Therapeutics Says Vascepa Now Reimbursed by British Columbia's Provincial Drug Plan	06/02
HLS Therapeutics Brief: Announcing that Vascepa is now reimbursed by British Columbia's Provincial Drug Plan	06/02
HLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan	06/02
HLS Therapeutics Inc. Announces CFO Changes	18/12
HLS Therapeutics Announcing CFO Departure; John Hanna appointed Interim CFO to replace departing CFO Tim Hendrickson	18/12
HLS Therapeutics Brief: Announcing CFO Departure; John Hanna appointed Interim CFO to replace departing CFO Tim Hendrickson	18/12
HLS Therapeutics Announces CFO Departure	18/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen HLS Therapeutics Inc.

Aandelen

HLS

CA40390B1094

Andere talen

Filters